-
1 Comment
Sino Biopharmaceutical Limited is currently in a long term downtrend where the price is trading 8.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.1.
Sino Biopharmaceutical Limited's total revenue rose by 12.4% to $6B since the same quarter in the previous year.
Its net income has increased by 104.0% to $921M since the same quarter in the previous year.
Based on the above factors, Sino Biopharmaceutical Limited gets an overall score of 3/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | KYG8167W1380 |
| Target Price | None |
|---|---|
| Dividend Yield | 1.9% |
| Beta | 0.75 |
| Market Cap | 8B |
| PE Ratio | 42.41 |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SMZ1.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
